Symbiomix Therapeutics closes $41M Series A

With a third infusion of investment, Symbiomix Therapeutics closed a $41 million Series A round, the company announced Wednesday.
Symbiomix, which is working to bring a single-dose treatment for bacterial vaginosis to market, also reported positive results when tested on 215 women in Phase II trials. Those results came just two months after successful Phase I trial results.
With the funding round closed and the latest trial complete, the company is set to speed up its process for getting the product to market, said Symbiomix President Robert Jacks.
The company, which has eight employees based at the Emerging Technology Centers, sold $32.5 million in equity in three phases from 2012-2015, and sold $8.5 million in debt over that time, Jacks said.
The money will allow the company to enter Phase III trials, which will be conducted at 20 sites across the country, one of which could be in Baltimore. That round of trials is expected to be completed by the end of the year. The company has a goal to get its treatment on the market in 2017.
Symbiomix also received a designation from the U.S. Food and Drug Administration that could speed up regulatory approval. The company’s candidate treatment, SYM-1219, became a Qualified Infectious Disease Product (QIDP), which makes it a priority for review.
The oral single-dose treatment is aimed at addressing BV, which infects more than 20 million women in the U.S. each year, and makes those women more likely contract other diseases, like STIs and HIV.
The current standard treatment for BV is metronidazole. For full treatment, patients must take two doses of the antibiotic a day for seven days straight.